Quick Answer
BioRestorative Therapies, Inc. reported Research And Development Expense of $10.09 million for the year ending 2025.
- BioRestorative Therapies, Inc. showed an increase of +50.5% in Research And Development Expense from 2024 to 2025.
- This data is from BioRestorative Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), BioRestorative Therapies, Inc.'s Research And Development Expense has grown by 86,773.2%.
- Historical annual values: Fiscal year 2025: $10.09 million | Fiscal year 2024: $6.71 million | Fiscal year 2023: $4.03 million | Fiscal year 2022: $3.51 million | Fiscal year 2021: $729.1 thousand | Fiscal year 2020: $876.8 thousand | Fiscal year 2019: $1.72 million | Fiscal year 2018: $1.51 million | Fiscal year 2017: $2.15 million | Fiscal year 2016: $2.88 million | Fiscal year 2015: $2.11 million | Fiscal year 2014: $1.43 million | Fiscal year 2013: $1.59 million | Fiscal year 2012: $756.8 thousand | Fiscal year 2011: $12.0 thousand | Fiscal year 2010: $11.6 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: